April 21, 2021 10:59 AM EDT
News Briefing

No­vo Nordisk to launch PhI­II obe­si­ty tri­al for oral semaglu­tide; Edi­Gene ex­tends Se­ries B with ad­di­tion­al $62M

Max Gelman

Senior Editor

On the heels of a high­ly suc­cess­ful tri­al for its block­buster di­a­betes drug semaglu­tide in obe­si­ty, No­vo Nordisk is prep­ping a Phase II­Ia study for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times